Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18666190 | ANTI-CXCR2 ANTIBODIES AND USES THEREOF | May 2024 | September 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18624726 | DUAL-FUNCTION PROTEIN FOR LIPID AND BLOOD GLUCOSE REGULATION | April 2024 | July 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18444110 | ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR BONE REGENERATION | February 2024 | September 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18401874 | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | January 2024 | July 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18396187 | ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF | December 2023 | August 2025 | Allow | 20 | 1 | 0 | No | No |
| 18538465 | ANTI-IL-36 ANTIBODIES AND METHODS OF USE THEREOF | December 2023 | May 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18509252 | BISPECIFIC ANTI-CCL2 ANTIBODIES | November 2023 | April 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18481884 | ANTIBODIES AGAINST TIM3 AND USES THEREOF | October 2023 | March 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18478374 | TREATMENT OF HIDRADENITIS SUPPURATIVA | September 2023 | April 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18464025 | ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES | September 2023 | February 2024 | Allow | 5 | 1 | 1 | No | No |
| 18335941 | BISPECIFIC ANTI-CCL2 ANTIBODIES | June 2023 | October 2025 | Allow | 29 | 1 | 1 | No | No |
| 18312897 | ANTI-OPG ANTIBODIES | May 2023 | June 2025 | Allow | 25 | 1 | 1 | No | No |
| 18126528 | METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSIS | March 2023 | October 2025 | Abandon | 31 | 2 | 0 | No | No |
| 18156016 | METHODS OF USE FOR IL-22 IN THE TREATMENT OF GASTROINTESTINAL GRAFT VS. HOST DISEASE | January 2023 | February 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18068506 | METHOD FOR PRODUCING DUAL FUNCTION PROTEINS AND ITS DERIVATIVES | December 2022 | June 2025 | Abandon | 30 | 1 | 1 | No | No |
| 18052180 | SINGLE-CHAIN TNF RECEPTOR 2 AGONIST FUSION PROTEINS | November 2022 | March 2025 | Allow | 28 | 2 | 0 | Yes | No |
| 17916337 | COMPOSITIONS AND METHODS FOR TREATING DYSREGULATED WOUND HEALING | September 2022 | March 2026 | Allow | 42 | 1 | 1 | No | No |
| 17906741 | PEPTIDE FOR PREVENTING OR TREATING HAIR LOSS, AND USE THEREOF | September 2022 | April 2025 | Allow | 31 | 1 | 0 | No | No |
| 17929232 | Aqueous Antibody Formulation Stabilized by Antioxidants for Parenteral Administration | September 2022 | July 2025 | Allow | 35 | 3 | 0 | No | No |
| 17823883 | PRODUCTION OF GLYCOPROTEINS USING MANGANESE | August 2022 | March 2025 | Allow | 30 | 2 | 0 | No | No |
| 17819200 | METHODS, REGIMENS, COMBINATIONS & ANTAGONISTS | August 2022 | July 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17818927 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES | August 2022 | April 2025 | Abandon | 32 | 1 | 1 | No | No |
| 17853218 | ANTI-CCL17 ANTIBODIES | June 2022 | May 2024 | Allow | 22 | 2 | 1 | No | No |
| 17785243 | Bispecific Caninized Antibodies and Bispecific Binding Partners for Treating Atopic Dermatitis | June 2022 | March 2026 | Allow | 45 | 1 | 1 | No | No |
| 17751433 | THYROID STIMULATING HORMONE COMPOSITIONS | May 2022 | October 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17737965 | METHODS OF TREATMENT USING A LEPTIN RECEPTOR AGONIST ANTIBODY | May 2022 | March 2025 | Allow | 35 | 3 | 0 | No | No |
| 17718622 | ANTI-CXCR2 ANTIBODIES AND USES THEREOF | April 2022 | February 2024 | Allow | 22 | 1 | 0 | No | No |
| 17700251 | RECOMBINANT HUMAN EPO-FC-FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO | March 2022 | April 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17761727 | DOSING FOR ANTI-TRYPTASE ANTIBODIES | March 2022 | December 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17639096 | CR2 Binding Proteins and their use in Medical Therapy | February 2022 | January 2026 | Allow | 47 | 1 | 1 | No | No |
| 17681219 | ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS | February 2022 | October 2023 | Allow | 20 | 1 | 1 | No | No |
| 17629730 | METHODS OF MEASURING CELL-MEDIATED KILLING BY EFFECTORS | January 2022 | January 2026 | Abandon | 47 | 1 | 1 | No | No |
| 17579683 | CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF | January 2022 | March 2025 | Abandon | 38 | 1 | 2 | No | No |
| 17579581 | METHODS OF TREATMENT OF MUSCULAR DYSTROPHIES | January 2022 | September 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17627506 | METHOD FOR SELF-ASSEMBLY OF A PROTEIN ON A SUBSTRATE IN A THREE-DIMENSIONAL HONEYCOMB STRUCTURE | January 2022 | November 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17572792 | METHOD FOR PROMOTING WOUND HEALING | January 2022 | January 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17571499 | USES OF ANTI-SIRPg ANTIBODIES | January 2022 | February 2025 | Allow | 37 | 3 | 1 | No | No |
| 17647210 | TREATMENT OF HIDRADENITIS SUPPURATIVA | January 2022 | October 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17570010 | METHODS OF TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS | January 2022 | September 2025 | Abandon | 45 | 2 | 0 | No | Yes |
| 17549017 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME | December 2021 | February 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17539034 | ANTIGEN-BINDING PROTEINS THAT ACTIVATE THE LEPTIN RECEPTOR | November 2021 | September 2023 | Allow | 21 | 1 | 0 | No | No |
| 17537020 | TOPICAL ERYTHROPOIETIN FORMULATIONS AND METHODS FOR IMPROVING WOUND HEALING WITH AND COSMETIC USE OF THE FORMULATIONS | November 2021 | June 2025 | Allow | 43 | 4 | 1 | No | Yes |
| 17534909 | CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENT | November 2021 | June 2025 | Abandon | 43 | 2 | 1 | No | No |
| 17612878 | ANTI-CD137L ANTIBODIES AND METHODS OF USING SAME | November 2021 | July 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17600842 | DIAGNOSIS AND TREATMENT FOR CHRONIC INFLAMMATION AND VIRUS INFECTION | October 2021 | June 2025 | Allow | 44 | 1 | 1 | No | No |
| 17486833 | METHODS OF TREATING MULTIPLE MYELOMA CANCERS EXPRESSING HIGH LEVELS OF EPO-RECEPTOR USING PSA-EPO | September 2021 | September 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17483967 | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND OX40L | September 2021 | August 2025 | Allow | 47 | 3 | 1 | No | No |
| 17473459 | COMPOSITIONS AND METHODS FOR REGULATING ERYTHROPOIESIS | September 2021 | November 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17410324 | PDGF RECEPTOR BETA BINDING POLYPEPTIDES | August 2021 | December 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17383319 | COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO | July 2021 | September 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17379504 | LONG-ACTING COAGULATION FACTORS AND METHODS OF PRODUCING SAME | July 2021 | May 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17338869 | METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSIS | June 2021 | June 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17293623 | ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS | May 2021 | April 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17193057 | Sustained Response Predictors After Treatment with Anti-IL23 Antibody | March 2021 | January 2026 | Allow | 58 | 5 | 0 | No | Yes |
| 17173214 | NBP158 AND USES THEREOF | February 2021 | June 2023 | Allow | 28 | 1 | 0 | No | No |
| 17172856 | ANTI-ACVR1 ANTIBODIES AND USES THEREOF | February 2021 | November 2023 | Allow | 33 | 1 | 1 | No | No |
| 17164438 | METHODS OF PRODUCING LONG ACTING CTP-MODIFIED POLYPEPTIDES | February 2021 | February 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17264470 | UNIVERSAL CHIMERIC RECEPTORS | January 2021 | September 2025 | Abandon | 56 | 2 | 1 | No | No |
| 17145653 | Method for purifying PEGylated erythropoietin | January 2021 | August 2023 | Allow | 31 | 1 | 0 | No | No |
| 17127766 | Variant Antibody That Binds Cd38 | December 2020 | December 2025 | Allow | 60 | 2 | 0 | No | No |
| 17123465 | BISPECIFIC ANTI-CCL2 ANTIBODIES | December 2020 | March 2023 | Allow | 27 | 0 | 1 | No | No |
| 17103260 | TREATMENT OF HIDRADENITIS SUPPURATIVA | November 2020 | January 2024 | Abandon | 37 | 2 | 0 | No | No |
| 17055646 | CH3 DOMAIN EPITOPE TAGS | November 2020 | March 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17050894 | REFRACTORY ASTHMA PROPHYLACTIC/THERAPEUTIC AGENT SCREENING METHOD, AND REFRACTORY ASTHMA PROPHYLACTIC/THERAPEUTIC AGENT | October 2020 | June 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17080268 | METHOD FOR TREATING PULMONARY FIBROSIS USING S100A3 PROTEIN | October 2020 | January 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17072298 | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | October 2020 | August 2024 | Abandon | 46 | 2 | 1 | No | Yes |
| 17048202 | FUSION PROTEIN BINDING TO CD47 PROTEIN AND APPLICATION THEREOF | October 2020 | August 2023 | Allow | 34 | 2 | 1 | No | No |
| 17060989 | METHODS FOR TREATING MYELODYSPLASTIC SYNDROMES AND SIDEROBLASTIC ANEMIAS | October 2020 | December 2022 | Abandon | 26 | 1 | 0 | No | No |
| 17060362 | ANTI-CCL17 ANTIBODIES | October 2020 | April 2022 | Allow | 18 | 0 | 0 | No | No |
| 16982759 | METHODS AND COMPOSITIONS FOR ALLERGIC DISORDERS | September 2020 | August 2023 | Abandon | 34 | 2 | 1 | No | No |
| 17002665 | USING COLIPASE INHIBITORS TO TREAT PANCREATITIS | August 2020 | May 2021 | Abandon | 9 | 1 | 0 | No | No |
| 16989505 | METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING SICKLE-CELL DISEASE | August 2020 | September 2024 | Abandon | 49 | 4 | 0 | No | No |
| 16988554 | NEMOLIZUMAB IN THE TREATMENT OF ATOPIC DERMATITIS WITH MODERATE TO SEVERE EXCORIATION | August 2020 | June 2025 | Allow | 58 | 6 | 1 | Yes | No |
| 16941272 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES | July 2020 | March 2022 | Allow | 19 | 0 | 0 | No | No |
| 16947265 | Production of Glycoproteins Using Manganese | July 2020 | December 2022 | Abandon | 29 | 2 | 0 | No | No |
| 16963311 | THERAPEUTIC AGENT FOR ASTHMA CONTAINING IL-6 INHIBITOR | July 2020 | December 2025 | Allow | 60 | 7 | 0 | No | No |
| 16959252 | THERAPEUTICS OF PTD-SMAD7 FUSION PROTEINS | June 2020 | September 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16957462 | PROCESS FOR PROVIDING PEGYLATED PROTEIN COMPOSITION | June 2020 | September 2024 | Allow | 51 | 4 | 0 | No | No |
| 16957160 | PROCESS FOR PROVIDING PEGYLATED PROTEIN COMPOSITION | June 2020 | August 2022 | Allow | 25 | 1 | 0 | No | No |
| 16772100 | Compositions and Methods for Treating or Preventing Endocrine FGF23-Linked Diseases | June 2020 | August 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16894265 | Methods For Treating Inflammatory Disorders and Traumatic Brain Injury Using Stabilized Non-Hematopoietic EPO Short Peptides | June 2020 | September 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16892973 | ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF | June 2020 | September 2023 | Allow | 40 | 1 | 1 | No | No |
| 16891413 | METHOD FOR PROMOTING WOUND HEALING | June 2020 | October 2021 | Allow | 16 | 2 | 0 | Yes | Yes |
| 16884905 | DUAL-FUNCTION PROTEIN FOR LIPID AND BLOOD GLUCOSE REGULATION | May 2020 | January 2024 | Allow | 43 | 4 | 1 | No | No |
| 16880831 | METHODS OF TREATMENT OF MUSCULAR DYSTROPHIES | May 2020 | May 2022 | Abandon | 24 | 2 | 1 | Yes | No |
| 16764788 | ANTI-IL-17 ANTIBODY/TNFR ECD FUSION PROTEIN AND USE THEREOF | May 2020 | January 2023 | Allow | 32 | 2 | 1 | No | No |
| 16875159 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AN ENHANCED PATIENT POPULATION USING BENRALIZUMAB | May 2020 | March 2024 | Abandon | 46 | 2 | 0 | No | No |
| 16611089 | METHOD FOR EXTENDING HALF-LIFE OF PROTEIN | May 2020 | November 2023 | Abandon | 49 | 2 | 1 | No | No |
| 16865086 | LONG-ACTING COAGULATION FACTORS AND METHODS OF PRODUCING SAME | May 2020 | March 2021 | Allow | 10 | 1 | 0 | No | No |
| 16855896 | PHARMACEUTICAL FORMULATIONS | April 2020 | November 2021 | Abandon | 19 | 1 | 0 | No | No |
| 16652815 | Novel Senolytic Peptides | April 2020 | January 2023 | Abandon | 34 | 2 | 1 | No | No |
| 16650632 | NOVEL CONJUGATES AND USES THEREOF | March 2020 | February 2022 | Abandon | 22 | 1 | 1 | No | No |
| 16797253 | ANTIBODIES TO HUMAN ERYTHROFERRONE AND USES THEREOF | February 2020 | July 2021 | Allow | 16 | 2 | 0 | No | No |
| 16792728 | PDGF RECEPTOR BETA BINDING POLYPEPTIDES | February 2020 | May 2021 | Allow | 15 | 1 | 1 | No | No |
| 16637093 | METHOD FOR TREATING CANCER USING CD14 ANTAGONISTS | February 2020 | November 2023 | Allow | 45 | 3 | 1 | No | No |
| 16782669 | ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES | February 2020 | March 2024 | Abandon | 49 | 2 | 1 | No | No |
| 16742759 | ULTRALONG COMPLEMENTARITY DETERMINING REGIONS AND USES THEREOF | January 2020 | March 2022 | Allow | 26 | 2 | 1 | No | No |
| 16628427 | FC-GAMMA RECEPTOR MUTANTS | January 2020 | January 2023 | Allow | 36 | 2 | 1 | No | No |
| 16724491 | METHODS OF USE FOR IL-22 IN THE TREATMENT OF GASTROINTESTINAL GRAFT VS. HOST DISEASE | December 2019 | August 2022 | Allow | 32 | 2 | 1 | Yes | No |
| 16722952 | CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENT | December 2019 | February 2022 | Abandon | 25 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DEBERRY, REGINA M.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DEBERRY, REGINA M works in Art Unit 1647 and has examined 786 patent applications in our dataset. With an allowance rate of 44.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner DEBERRY, REGINA M's allowance rate of 44.8% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DEBERRY, REGINA M receive 2.39 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DEBERRY, REGINA M is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +38.3% benefit to allowance rate for applications examined by DEBERRY, REGINA M. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.0% of applications are subsequently allowed. This success rate is in the 14% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 44.6% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 87.5% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 83.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 76.4% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 7.9% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.0% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.